Press Releases for MEDX

Press Releases
Bristol-Myers Squibb Completes Acquisition of Medarex, Inc.
Bristol-Myers Squibb Completes Initial Tender Offer for Medarex, Inc. With 87.7% of Shares Tendered; Announces Subsequent Offering Period
Bristol-Myers Squibb Extends Tender Offer for Medarex, Inc.
BenchmarkJournal.Com Free Analyst Review for KERX, MEDX, AMCC, HBAN, JBLU and LNCR
Brower Piven Announces the Filing of Class Action Lawsuit Against Medarex, Inc.
Harwood Feffer LLP Files Class Action On Behalf of Shareholders of Medarex, Inc. -- MEDX
Medarex Announces 2009 Second Quarter Financial Results
Bristol-Myers Squibb Begins Tender Offer to Acquire Medarex, Inc.
Fitch Expects Bristol-Myers Squibb's Ratings to Be Unaffected By Medarex Acquisition
Bristol-Myers Squibb to Acquire Medarex
Medarex to Receive Milestone Payment from FibroGen for the Initiation of a Phase 2 Study of FG-3019 in Patients with Diabetic Kidney Disease
Medarex and Lonza Sign Collaboration Agreement for the Supply of Antibody-Based Products
Medarex to Receive Milestone Payment for the Approval of Ilaris for the Treatment of Cryopyrin-Associated Periodic Syndrome
SmallCapSentinel.Com Identifies Market Actives: IFSL, MNTG, TSTR, LVLT, MEDX, SATC
SmallCapSentinel.Com Identifies Market Actives: IFSL, MNTG, TSTR, LVLT, MEDX, SATC
Medarex to Present at Three Upcoming Investor Conferences
Medarex Announces Efficacy Data in Cancer Patients Treated with Investigational Anti-PD-1 Antibody at American Society of Clinical Oncology Annual Meeting
Results from Three Phase 2 Studies Reported a Two-Year Survival Rate Ranging from 30 to 42 Percent in Metastatic Melanoma Patients Treated with Ipilimumab (10 mg/kg)
Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-CXCR4 Antibody, MDX-1338
Medarex to Host Clinical Program Update Conference Call on Tuesday, June 2, 2009
Medarex Announces Primary Endpoint Achieved in MDX-1100 Anti-IP-10 Antibody Phase 2 Trial for Rheumatoid Arthritis
MaybachFinancial.Com Posts Free Analyst Report on CBSH, ATPG, MELI and MEDX
Medarex to Present at the Bank of America and Merrill Lynch Health Care Conference
Medarex Announces 2009 First Quarter Financial Results
Medarex to Host Business and Financial Update Conference Call on Thursday, April 30, 2009
Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
Medarex Announces Preclinical Data from Multiple Research Programs Demonstrating Anti-Tumor Activity in Cancer
Merck & Co., Inc., Medarex, Inc. and Massachusetts Biologic Laboratories Sign Exclusive Licensing Agreement for Investigational Monoclonal Antibody Combination for Clostridium Difficile Infection
Medarex Announces Clinical Data for MDX-1401 in Hodgkin's Lymphoma at Annual Meeting of the American Association for Cancer Research
Medarex to Receive Milestone Payment for Approval of SIMPONI(TM) for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
AnalystChoice.Com Free Investment Opinion on PPDI, MEDX, CVTX and OSIP
Medarex Highlights Oncology Pipeline at Needham Cancer Therapeutics Conference in New York City
Medarex to Present at the Needham Cancer Therapeutics Conference
Medarex Announces 2008 Fourth Quarter and Year End Financial Results
PharmAthene Presents Data for SparVax(TM) and Valortim(R), a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense Meeting
Medarex to Announce 2008 Fourth Quarter and Year-End Financial Results on Wednesday, February 25, 2009
Medarex Announces Allowance of Investigational New Drug Application for Company's First Antibody-Drug Conjugate, MDX-1203
Medarex Reviews Recent Highlights and Outlook for 2009
Medarex to Present at the 27th Annual J.P. Morgan Healthcare Conference
Medarex to Receive Milestone Payment for Approval of STELARA(TM) (Ustekinumab) for the Treatment of Moderate to Severe Plaque Psoriasis
Medarex Announces Enhanced Activity Data with Second Generation Anti-CD30 Antibody for Malignant Lymphoma
Medarex to Present at the RBC Capital Markets Healthcare Conference
Medarex Announces Initiation of Phase 1b Clinical Development Program with MDX-1106 for the Treatment of Cancer
Medarex Receives Milestone Payment for Investigational Antibody Targeting Integrin Receptors
Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD)
Medarex Announces 2008 Third Quarter Financial Results
Medarex And PharmAthene Announce New Therapeutic Data for Anthrax Anti-Toxin, Valortim(R)
PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop
Medarex to Present at the UBS Global Life Sciences Conference
Updated Survival Data from Three Phase 2 Ipilimumab Studies Showed Almost Half of Previously Treated Metastatic Melanoma Patients Alive Beyond One Year
Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing
Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology
Medarex to Present at the Thomas Weisel Partners Healthcare Conference
Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus
Medarex Announces 2008 Second Quarter Financial Results
Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-PD-L1 Antibody, MDX-1105
Medarex Receives Milestone Payment for Acceptance of Investigational New Drug Application
BioWa and Medarex Announce License of BioWa's COMPLEGENT(TM) Technology
Medarex Highlights Strength in Antibody Development and Underlying Pipeline Strategy at R&D Day Event in New York City
Medarex Announces July 10 Live Webcast of R&D Day Event
Medarex to Present at the Jefferies Second Annual Healthcare Conference
Medarex to Present at the 29th Annual Goldman Sachs Healthcare Conference
Interim Phase 1/2 Data of Ipilimumab in Prostate Cancer Presented at American Society of Clinical Oncology Annual Meeting
Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting
Ipilimumab Plus Chemotherapy is Associated with Prolonged Survival and Increased Disease Control Rates in Patients with Advanced Melanoma
New Ipilimumab Survival Data in Patients with Metastatic Melanoma Presented at American Society of Clinical Oncology Annual Meeting
Medarex Hosts June 2nd Webcast of Ipilimumab Data Presented at ASCO
Medarex Reports Phase 1 Clinical Data of MDX-1100 at Digestive Disease Week - May 27 2008 12:59AM
Medarex Announces June 2nd Webcast Review and Discussion of Ipilimumab Data Presented at ASCO - May 27 2008 12:55AM
BellwetherReport.com Analyst Report on IOMI, EMKR, GIGM and MEDX - May 27 2008 1:21AM
Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis - Jun 2 2008 12:55AM
Medarex Announces 2008 First Quarter Financial Results - Jun 2 2008 12:55AM
Medarex to Present at the Bank of America 2008 Healthcare Conference - Jun 2 2008 12:55AM
Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
New Analyst Reports for BENCHMARK ENERGY CORP, MEDAREX INC, NEUROMETRIX INC, and INTEGRATED DEVICE TECHNOLOGY INC - May 27 2008 1:16AM
Medarex and Bristol-Myers Squibb Joint Statement on Submission Status of Ipilimumab
Medarex to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Medarex Reports Phase 1/2 Clinical Data of MDX-060 in Lymphoma at American Association for Cancer Research Meeting
Medarex Reports Preclinical Data on Multiple Antibody-Drug Conjugate Candidates at American Association for Cancer Research Meeting
Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
Stocks Trading Report for Thursday! April 3, 2008
Medarex Announces Ipilimumab Program Continues to Move Forward
BellwetherReport.com Free Analyst Review for CTIC, MEDX, CROX and TSL